As per the Opinions of the General Office of the CPC Central Committee and the General Office of the State Council on Deepening the Reform of Review & Approval System to Encourage Innovation in Drugs and Medical Devices (General Office [2017] No. 42), and the Announcement on Adjusting the Review & Approval Items of APIs, Pharmaceutical Excipients and Packaging Materials (Announcement No. 146 of 2017) issued by the former CFDA, on July 16, 2019, NMPA issued the Announcement on Issues Concerning the Further Improvement of Drug-related Associated Review & Approval and Supervision, to further clarify the administrative details for associated review & approval and supervision of APIs, pharmaceutical excipients, packaging materials and containers in direct contact with pharmaceuticals (hereinafter referred to as AEP: APIs+ excipients + packaging) with drugs/preparations).